MedImmune Expects Initial Data From Head-To-Head Numax/Synagis Trial Before Nov. 23

While the firm anticipates a superiority finding, the study comparing its RSV therapies is powered for both superiority and non-inferiority, MedImmune execs say during Q3 call.